Lnbloc 5 Tablet contains Cilnidipine 5 mg, a calcium channel blocker used primarily for the management of hypertension. Cilnidipine selectively inhibits L-type and N-type calcium channels, resulting in vasodilation of peripheral arteries and reduction of peripheral vascular resistance, thereby lowering blood pressure. The dual blockade mechanism not only decreases arterial pressure but also modulates sympathetic nerve activity, which may contribute to improved cardiovascular outcomes. Lnbloc 5 is indicated for the treatment of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is effective in reducing both systolic and diastolic blood pressure, helping to prevent complications associated with uncontrolled hypertension such as stroke, myocardial infarction, and renal impairment. The drug is generally well-tolerated, with common adverse effects including headache, dizziness, and peripheral edema. Lnbloc 5 should be used cautiously in patients with severe hepatic impairment and is contraindicated in individuals with known hypersensitivity to Cilnidipine or other dihydropyridine calcium channel blockers. Regular monitoring of blood pressure and clinical status is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability.